Investigational Therapeutic Antibody
Existing checkpoint inhibitors against targets such as PD-1/PD-L1 and CTLA-4 are ineffective for a majority of cancer patients, especially those with immunologically cold tumors. By targeting an alternative checkpoint, CD200R1, 23ME-00610 has the potential to activate a broader swath of immune cells to attack cancer.
Strong human genetic evidence supports a role for the CD200R1 pathway in immune surveillance, with three of its components – CD200R1 itself, its ligand CD200 and the downstream signaling protein DOK2 – significantly associated with opposing genetic risk for oncology versus immunologic diseases. The expression of CD200R1 by T cells, NK cells, macrophages and granulocytes gives 23ME-00610 the potential to activate innate and adaptive immunity against tumors and has the potential for clinical activity as a monotherapy.
23ME-00610 is a potentially first-in-class, investigational, fully humanized, effectorless IgG1 antibody generated in-house by 23andMe Therapeutics.
23ME-00610: Phase 1/2a Clinical Trial
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610.